Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PreticX is a branded prebiotic ingredient composed of xylooligosaccharides (XOS), primarily derived from non-GMO corn cobs. Developed by AIDP, Inc., it is designed to selectively stimulate the growth of beneficial gut bacteria, such as *Bifidobacterium*, at significantly lower doses than traditional prebiotics like inulin or fructooligosaccharides (FOS). Clinical research, including studies in overweight adults, has demonstrated that PreticX can help reduce visceral adipose tissue, lower systemic inflammation markers, and improve metabolic health. It is commonly used in dietary supplements and functional foods to support gut health and immune function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xylooligosaccharide.